2016
Inhibition of renalase expression and signaling has antitumor activity in pancreatic cancer
Guo X, Hollander L, MacPherson D, Wang L, Velazquez H, Chang J, Safirstein R, Cha C, Gorelick F, Desir GV. Inhibition of renalase expression and signaling has antitumor activity in pancreatic cancer. Scientific Reports 2016, 6: 22996. PMID: 26972355, PMCID: PMC4789641, DOI: 10.1038/srep22996.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnimalsAntibodiesApoptosisCarcinoma, Pancreatic DuctalCell Cycle CheckpointsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryKaplan-Meier EstimateMaleMice, NudeMiddle AgedMonoamine OxidasePancreatic NeoplasmsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReverse Transcriptase Polymerase Chain ReactionRNA InterferenceSignal TransductionXenograft Model Antitumor AssaysConceptsRenalase expressionPancreatic cancerPancreatic ductal adenocarcinoma growthCohort of patientsPancreatic cancer tissuesPancreatic ductal adenocarcinomaPancreatic ductal adenocarcinoma cellsXenograft mouse modelAttractive therapeutic targetDuctal adenocarcinoma cellsTumor cell apoptosisOverall survivalPathogenic roleCell cycle arrestDuctal adenocarcinomaPrognostic makerTumor massMouse modelTherapeutic targetCellular injuryCancer tissuesRenalaseCancerAdenocarcinoma cellsGrowth factor
2005
Kv1.3 potassium channel blockade as an approach to insulin resistance
Desir GV. Kv1.3 potassium channel blockade as an approach to insulin resistance. Expert Opinion On Therapeutic Targets 2005, 9: 571-579. PMID: 15948674, DOI: 10.1517/14728222.9.3.571.Peer-Reviewed Original ResearchConceptsInsulin resistanceInsulin sensitivityKv1.3 channel inhibitionPotassium channel blockadePeripheral insulin sensitivityPotential therapeutic targetDevastating metabolic diseaseType II diabetesVoltage-gated potassium channelsAbnormal glucoseDiabetes mellitusInsulin deficiencyDevelopment of drugsInflammatory cytokinesChannel blockadeGlucose metabolismTherapeutic targetCardinal featuresMetabolic diseasesChannel inhibitionII diabetesLipid metabolismHealthcare expendituresPotassium channelsPromising target